Diabetes Care, Vol 10, Issue 1 68-71, Copyright © 1987 by American Diabetes Association

ARTICLES

No glycemic benefit from guar administration in NIDDM

RR Holman, J Steemson, P Darling and RC Turner

A randomized crossover study of 5-g guar minitablets against placebo, given three times per day with main meals for 8 wk, was done in 29 non-insulin-dependent diabetes mellitus (NIDDM) patients who had near-normal fasting plasma glucose concentrations on treatment with diet alone, additional sulfonylurea, or ultralente insulin. Guar did not reduce the excessive postprandial glycemic excursion, glycosylated hemoglobin values, basal plasma glucose concentrations, basal or incremental plasma C-peptide values, or body weight. There were few side effects with either guar or placebo therapy. Mean low-density lipoprotein cholesterol levels were significantly reduced (P less than .001) by guar administration (116 +/- 23 vs. 104 +/- 19 mg/dl). Guar additives did not improve the excessive postprandial glycemia found in NIDDM patients in whom near-normal fasting plasma glucose levels had been obtained.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Chandalia, A. Garg, D. Lutjohann, K. von Bergmann, S. M. Grundy, and L. J. Brinkley Beneficial Effects of High Dietary Fiber Intake in Patients with Type 2 Diabetes Mellitus N. Engl. J. Med., May 11, 2000; 342(19): 1392 - 1398. [Abstract] [Full Text] [PDF]

				L. Brown, B. Rosner, W. W Willett, and F. M Sacks Cholesterol-lowering effects of dietary fiber: a meta-analysis Am. J. Clinical Nutrition, January 1, 1999; 69(1): 30 - 42. [Abstract] [Full Text] [PDF]